Literature DB >> 22104584

Antimicrobial resistance of Actinobacillus pleuropneumoniae isolated from swine.

Michele Vanni1, Marianna Merenda, Giuseppe Barigazzi, Chiara Garbarino, Andrea Luppi, Rosalba Tognetti, Luigi Intorre.   

Abstract

The aim of this retrospective study was to evaluate the antimicrobial resistance rates and the trend in resistance of Actinobacillus pleuropneumoniae isolated from pigs in Italy from 1994 to 2009. A total of 992 A. pleuropneumoniae isolates were tested for their susceptibility to a panel of antimicrobial agents in a disk diffusion method. Resistance to 7 drugs (amoxicillin, amoxicillin/clavulanic acid, ampicillin, cefquinome, cotrimoxazole, penicillin G and tilmicosin) showed a significant increasing trend over the time, while for 2 drugs (gentamycin and marbofloxacin) a significant decrease was observed. Resistance to the remaining 14 antimicrobial agents tested did not change significantly over the study period. Most of the isolates retained high susceptibility to antimicrobials usually effective against A. pleuropneumoniae such as amphenicols, fluoroquinolones and ceftiofur. However, high rates of resistance were observed for potentiated sulfa drugs, tetracyclines and penicillins which are currently recommended antimicrobials for pig pleuropneumonia therapy. Our results suggest the importance of continued monitoring of A. pleuropneumoniae clinical isolates in order to choose the most appropriate treatment of infections and to control the increase of resistance to currently used antimicrobials. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104584     DOI: 10.1016/j.vetmic.2011.10.022

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  18 in total

1.  Assessment of animal diseases caused by bacteria resistant to antimicrobials: Swine.

Authors:  Søren Saxmose Nielsen; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; Jose Luis Gonzales Rojas; Christian Gortazar Schmidt; Mette Herskin; Virginie Michel; Miguel Angel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Helen Clare Roberts; Liisa Helena Sihvonen; Hans Spoolder; Karl Stahl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Jeroen Dewulf; Luca Guardabassi; Friederike Hilbert; Rodolphe Mader; Francesca Baldinelli; Julio Alvarez
Journal:  EFSA J       Date:  2021-12-24

2.  Broad activity against porcine bacterial pathogens displayed by two insect antimicrobial peptides moricin and cecropin B.

Authors:  Han Hu; Chunmei Wang; Xiaozhen Guo; Wentao Li; Yang Wang; Qigai He
Journal:  Mol Cells       Date:  2013-02-21       Impact factor: 5.034

3.  Characterisation of a mobilisable plasmid conferring florfenicol and chloramphenicol resistance in Actinobacillus pleuropneumoniae.

Authors:  Janine T Bossé; Yanwen Li; Tom G Atherton; Stephanie Walker; Susanna M Williamson; Jon Rogers; Roy R Chaudhuri; Lucy A Weinert; Matthew T G Holden; Duncan J Maskell; Alexander W Tucker; Brendan W Wren; Andrew N Rycroft; Paul R Langford
Journal:  Vet Microbiol       Date:  2015-05-28       Impact factor: 3.293

4.  Immunoprotective Efficacy of Six In vivo-Induced Antigens against Actinobacillus pleuropneumoniae as Potential Vaccine Candidates in Murine Model.

Authors:  Fei Zhang; Sanjie Cao; Zhuang Zhu; Yusheng Yang; Xintian Wen; Yung-Fu Chang; Xiaobo Huang; Rui Wu; Yiping Wen; Qigui Yan; Yong Huang; Xiaoping Ma; Qin Zhao
Journal:  Front Microbiol       Date:  2016-10-21       Impact factor: 5.640

5.  In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.

Authors:  Fabio Antenucci; Cyrielle Fougeroux; Alannah Deeney; Cathrine Ørskov; Andrew Rycroft; Peter Johannes Holst; Anders Miki Bojesen
Journal:  Vet Res       Date:  2018-01-09       Impact factor: 3.683

6.  p518, a small floR plasmid from a South American isolate of Actinobacillus pleuropneumoniae.

Authors:  Giarlã Cunha da Silva; Ciro César Rossi; Mateus Ferreira Santana; Paul R Langford; Janine T Bossé; Denise Mara Soares Bazzolli
Journal:  Vet Microbiol       Date:  2017-04-23       Impact factor: 3.293

7.  Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe.

Authors:  Erik Grandemange; Pierre-Alexandre Perrin; Dejean Cvejic; Miriam Haas; Tim Rowan; Klaus Hellmann
Journal:  Porcine Health Manag       Date:  2017-05-10

8.  Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates of Actinobacillus pleuropneumoniae.

Authors:  Md Akil Hossain; Hae-Chul Park; Kyunghun Jeong; Yang Ho Jang; Dae Gyun Kim; JeongWoo Kang; Kwang-Jick Lee
Journal:  Biomed Res Int       Date:  2017-04-06       Impact factor: 3.411

9.  Etiology of acute respiratory disease in fattening pigs in Finland.

Authors:  Minna Haimi-Hakala; Outi Hälli; Tapio Laurila; Mirja Raunio-Saarnisto; Tiina Nokireki; Taina Laine; Suvi Nykäsenoja; Kirsti Pelkola; Joaquim Segales; Marina Sibila; Claudio Oliviero; Olli Peltoniemi; Sinikka Pelkonen; Mari Heinonen
Journal:  Porcine Health Manag       Date:  2017-08-23

10.  Transcript profiling of the immunological interactions between Actinobacillus pleuropneumoniae serotype 7 and the host by dual RNA-seq.

Authors:  Ping Li; Zhiwen Xu; Xiangang Sun; Yue Yin; Yi Fan; Jun Zhao; Xiyu Mao; Jianbo Huang; Fan Yang; Ling Zhu
Journal:  BMC Microbiol       Date:  2017-09-12       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.